The Model Organism Development and Evaluation for Late-onset Alzheimer’s Disease (MODEL-AD) Consortium was established to maximize human datasets to identify putative variants, genes, and biomarkers for AD; to generate, characterize, and validate the next generation of mouse models of AD; and to develop a preclinical testing pipeline.


Goals of the MODEL-AD Consortium are:

  • Develop the next generation of in vivo AD models based on human data
  • Institute a standardized and rigorous process for characterization of animal models
  • Align the pathophysiological features of AD models with corresponding stages of clinical disease using translatable biomarkers
  • Establish guidelines for rigorous preclinical testing in animal models
  • Ensure rapid availability of animal models, protocols and validation data to all researchers for preclinical drug development

Contact us:

The MODEL-AD Consortium is a collaboration of: